We are the largest UK funder of EB research. We have invested over £20m and have been responsible, through funding pioneering research and working internationally, for establishing much of what is now known about EB.

This is our first research strategy to focus on impact and on what matters to people living with EB. Our ambition is to find and fund treatments to lessen the day-to-day impact of EB, and cures to eradicate EB.

Our new strategy puts patient outputs front and centre, with a focus on translational research that will have a positive impact on those with EB today. We will fund science of the highest quality across the world that has the potential to deliver for EB patients.

Our four overarching research priorities are those we view most likely to deliver outputs for people living with EB. They are:

• invest in drug re-purposing and develop drug discovery programmes to accelerate finding treatments
• increase investment in patient-centred research themes
• continue to invest to understand better the causes and progression of EB and the role of the immune system
• invest heavily in the next generation of EB researchers.

We are calling on the scientific community, funders and our industry partners to come and join us on this journey to accelerate EB research innovation.

Applications are welcome from all disciplines committed to improving the lives of people with EB.

Contact [email protected].

Read the full strategy here